
April 15 (Reuters) - MetaVia Inc MTVA.O:
METAVIA ANNOUNCES POSITIVE TOP-LINE DATA FROM THE 4-WEEK PHASE 1 MAD TRIAL OF DA-1726, A NOVEL 3:1 RATIO GLP-1 GLUCAGON DUAL RECEPTOR AGONIST TO TREAT OBESITY, SHOWING COMPELLING WEIGHT LOSS AND SAFETY EFFECTS WITH POTENTIAL BEST-IN-CLASS GLUCOSE CONTROL (GLP-1R), WAIST REDUCTION (GCGR), AND TOLERABILITY
METAVIA INC: ADDITIONAL COHORTS BEING ADDED TO DETERMINE MAXIMUM TOLERATED DOSE
METAVIA INC: STUDY SHOWS STRONG SIGNAL OF GLUCAGON EFFICACY AT DAY 33 AT 32 MG DOS
METAVIA: WITH NO TITRATION, DEMONSTRATED MAXIMUM WEIGHT LOSS OF 6.3% AND MEAN WEIGHT LOSS OF 4.3% AT DAY 26 AT 32 MG DOSE
METAVIA: PHASE 1 PART 3 TO INCLUDE WEGOVY EARLY DROP-OUT PATIENTS TO EXPLORE POTENTIAL SUPERIORITY OF DA-1726 ON SAFETY AND TOLERABILITY